These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32926754)

  • 61. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
    Hida Y; Imamura T; Kinugawa K
    J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial.
    Arai H; Yamashita S; Araki E; Yokote K; Tanigawa R; Saito A; Yamasaki S; Suganami H; Ishibashi S
    J Atheroscler Thromb; 2024 Apr; ():. PubMed ID: 38616112
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.
    Dohil R; Schmeltzer S; Cabrera BL; Wang T; Durelle J; Duke KB; Schwimmer JB; Lavine JE
    Aliment Pharmacol Ther; 2011 May; 33(9):1036-44. PubMed ID: 21395631
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
    Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
    Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese.
    Pardina E; Ferrer R; Rossell J; Baena-Fustegueras JA; Lecube A; Fort JM; Caubet E; González Ó; Vilallonga R; Vargas V; Balibrea JM; Peinado-Onsurbe J
    BBA Clin; 2016 Jun; 5():54-65. PubMed ID: 27051590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
    Sumida Y; Toyoda H; Yasuda S; Kimoto S; Sakamoto K; Nakade Y; Ito K; Osonoi T; Yoneda M
    J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38777770
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial.
    Panahi Y; Kianpour P; Mohtashami R; Atkin SL; Butler AE; Jafari R; Badeli R; Sahebkar A
    Phytother Res; 2018 Jul; 32(7):1382-1387. PubMed ID: 29520889
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Saturated fatty acid (SFA) status and SFA intake exhibit different relations with serum total cholesterol and lipoprotein cholesterol: a mechanistic explanation centered around lifestyle-induced low-grade inflammation.
    Ruiz-Núñez B; Kuipers RS; Luxwolda MF; De Graaf DJ; Breeuwsma BB; Dijck-Brouwer DA; Muskiet FA
    J Nutr Biochem; 2014 Mar; 25(3):304-12. PubMed ID: 24524903
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome.
    Iwakura T; Yasu T; Tomoe T; Ueno A; Sugiyama T; Otani N; Kawamoto S; Nakajima H
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836015
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver.
    Tomizawa M; Kawanabe Y; Shinozaki F; Sato S; Motoyoshi Y; Sugiyama T; Yamamoto S; Sueishi M
    Exp Ther Med; 2014 Sep; 8(3):759-762. PubMed ID: 25120595
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
    Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
    J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model.
    Tomita Y; Ozawa N; Miwa Y; Ishida A; Ohta M; Tsubota K; Kurihara T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio.
    Imamura T; Narang N; Kinugawa K
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628945
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
    Chen LH; Wang YF; Xu QH; Chen SS
    Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease.
    Oza N; Takahashi H; Eguchi Y; Kitajima Y; Kuwashiro T; Ishibashi E; Nakashita S; Iwane S; Kawaguchi Y; Mizuta T; Ozaki I; Ono N; Eguchi T; Fujimoto K; Anzai K
    Hepatol Res; 2014 Jul; 44(7):812-7. PubMed ID: 23721476
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
    Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
    Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
    Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes.
    Hsieh CJ; Wang PW; Hu TH
    PLoS One; 2015; 10(6):e0127521. PubMed ID: 26042596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.